Skip to Content
Merck
CN

Key Documents

View All Documentation

HNABTMAG-68K

MILLIPLEX® Human Neuroscience Panel

Configurable Human Amyloid Beta and Tau 4-Plex Panel

Synonym(s):

Human Neuroscience Protein Multiplex Assay, Luminex® Human Neuroscience Panel, Millipore Human Neuroscience Immunoassay

Sign In to View Organizational & Contract Pricing.

About This Item

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

cerebrospinal fluid(s) (CSF)

assay range

accuracy: 109%
(Spike recovery for Aβ1-42), accuracy: 91%
(Spike recovery for pTau181), accuracy: 98%
(Spike recovery for tTau), sensitivity: 1.5 pg/mL
(pTau181; MinDC+2SD), sensitivity: 10.2 pg/mL
(Aβ1-40; MinDC+2SD), sensitivity: 14.2 pg/mL
(tTau; MinDC+2SD), sensitivity: 2.5 pg/mL
(Aβ1-42; MinDC+2SD), standard curve range: 0.7-500 pg/mL
(pTau181), standard curve range: 11-8000 pg/mL
(tTau), standard curve range: 2-2000 pg/mL
(Aβ1-42), standard curve range: 21-15000 pg/mL
(Aβ1-40), inter-assay cv: <15%
intra-assay cv: <10%

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Alzheimer′s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, affecting approximately 36 million people worldwide. The disease is characterized by two key features: extracellular amyloid β (Aβ) plaques formed from peptides like Aβ1-40 and Aβ1-42, and intracellular neurofibrillary tangles composed of hyperphosphorylated Tau protein. These biomarkers—reduced soluble Aβ1-42, increased total Tau, and phosphorylated Tau in cerebrospinal fluid—serve as critical indicators of the pathological processes underlying neurodegenerative conditions.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 4 analytes in human cerebrospinal fluid (CSF).

Analytes included: Amyloid beta 1-40 (Aβ40), Amyloid beta 1-42 (Aβ42), Total Tau proteins (tTau), and Phosphorylated Tau Thr181 (pTau181).

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • Harness Mutliplexing Efficiency: Simultaneously measure both Aβ40 and Aβ42 in a single assay, accelerating your neurodegenerative disease research while maximizing laboratory throughput.
  • Built-in Reliability: Every kit undergoes rigorous validation to deliver unwavering consistency across batches, giving you the confidence to pursue breakthrough discoveries without questioning your data integrity.
  • Biologically Relevant Results: Our specially formulated serum matrix replicates physiological conditions, ensuring your findings accurately measure the analytes of interest.
  • Complete Research Solution: Eliminate procurement headaches with our comprehensive kit containing all essential components, allowing you to focus on scientific discovery rather than logistical challenges.
  • Accelerate Scientific Impact: Transform precise biomarker measurements into actionable insights that drive forward our understanding of Alzheimer′s disease and related amyloidopathies.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Still not finding the right product?

Explore all of our products under MILLIPLEX® Human Neuroscience Panel

pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Skin Sens. 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Regulatory Information

新产品

This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Protocols

Alzheimer’s In A Dish™: 3D Neural Stem Cell Models of Alzheimer's Disease

A stem cell culture protocol to generate 3D NSC models of Alzheimer’s disease using ReNcell human neural stem cell lines.

Related Content

阿尔茨海默病生物标记物多重和高灵敏度免疫测定

了解如何结合MILLIPLEX®多重和单分子计数(SMC®)高灵敏度蛋白免疫测定技术，检测人脑脊液、血浆和血清样本中的阿尔茨海默病(AD)生物标志物，开展神经科学深度研究。

Overview of Luminex® Multiplex Assay Technology | MILLIPLEX® Multiplex Assays

Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.

Detection of Alzheimer’s Disease Biomarkers | MILLIPLEX® Assays

Learn how multiplex detection of Alzheimer’s disease biomarkers, using the MILLIPLEX® Human Amyloid Beta and Tau Magnetic Bead Panel, allows for a different perspective on neurodegenerative disease research.

View All Related Content
Grace E Weber et al.
Journal of immunology (Baltimore, Md. : 1950), 204(5), 1111-1118 (2020-01-22)
Individuals with Down syndrome (DS) develop Alzheimer's disease (AD)-related neuropathology, characterized by amyloid plaques with amyloid β (Aβ) and neurofibrillary tangles with tau accumulation. Peripheral inflammation and the innate immune response are elevated in DS. Triggering receptor expressed in myeloid
Charbel Moussa et al.
Journal of neuroinflammation, 14(1), 1-1 (2017-01-15)
Treatment of mild-moderate Alzheimer's disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores. For this retrospective study
Monica Javidnia et al.
Journal of Alzheimer's disease : JAD, 60(2), 461-481 (2017-09-05)
Hyperphosphorylation and aggregation of tau protein is a critical factor in many neurodegenerative diseases. These diseases are increasing in prevalence, and there are currently no cures. Previous work from our group and others has shown that tyrosine kinase inhibitors (TKIs)